NCT02602327 - Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 9, 2017

Primary Completion Date

May 20, 2021

Study Completion Date

August 31, 2021

Conditions

Colon CancerRectal CancerLiver Metastases

Interventions

DRUG

Tas-102

Oral nucleoside antitumor agent consisting of α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.

DEVICE

SIR-Sphere

20-60mm resin microspheres containing Yttrium-90 (90Y, Y90) radioisotope

Trial Locations (1)

94143

University of California San Francisco, San Francisco